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Abstract
 
Human macrophages found in juxtaposition to fragmented elastin in vivo express the elastolytic
matrix metalloproteinases (MMPs) progelatinase B, prometalloelastase, and promatrilysin.
Though MMPs can degrade a range of extracellular matrix components, increasing evidence
 
suggests that preferred targets in vivo include nonmatrix substrates such as chemokines and growth
factors. Hence, the means by which MMPs participate in elastin turnover remain undefined as
does the identity of the elastolysins. Herein, human macrophage cultures have been established
that express a complement of elastolytic proteinases similar, if not identical, to that found in
vivo. Under plasminogen-free conditions, macrophages preferentially use metalloelastase to
mediate elastolysis via a process that deposits active enzyme on elastin surfaces. By contrast, in
the presence of plasminogen, human macrophages up-regulate proteolysis 10-fold by processing
promatrilysin to an active elastolysin via a urokinase-type plasminogen activator-dependent
pathway. Matrilysin-deficient human macrophages fail to mediate an elastolytic response
despite the continued expression of gelatinase B and metalloelastase. Thus, acting in concert
with cosecreted cysteine proteinases whose activities are constrained to sites of macrophage-
elastin contact (Punturieri, A., S. Filippov, E. Allen, I. Caras, R. Murray, V. Reddy, and
S.J. Weiss. 2000. 
 
J. Exp. Med.
 
 192:789–799), matrilysin confers macrophages with their
most potent MMP-dependent elastolytic system.
Key words: cysteine proteinase • elastin • macrophage • matrix metalloproteinase • plasminogen
 
Introduction
 
Macrophage-derived matrix metalloproteinases (MMPs)
play key roles in the elastolytic phenotypes pathognomonic
of atherosclerosis, aneurysm formation, and emphysema
(1–6). Based largely on studies performed in gene-deleted
mice, attention has focused on the role of the MMPs,
gelatinase B, and metalloelastase, as important mediators of
macrophage-mediated elastin degradation in vivo (3, 7, 8).
In these settings, macrophages are thought to secrete latent
MMP zymogens that undergo processing to active forms
after proteolytic removal of their respective propeptide
domains by plasmin, a product of the plasminogen activator-
plasminogen system (5, 6). However, although early
reports assumed that macrophages use plasmin-activated
gelatinase B or metalloelastase as direct acting elastolysins
(3, 7, 8), recent studies indicate that these MMPs more
likely control elastin turnover indirectly by preferentially
regulating proinflammatory events in vivo as a consequence
of their ability to (a) proteolyze nonextracellular matrix
(ECM) targets including antiproteinases, growth factors,
cytokines, chemokines, as well as cell adhesion molecules
and (b) regulate the expression and activity of downstream
proteolytic systems that might play a more direct role in
elastin degradation (9–11).
Given an inherent inability to identify the proteinases
directly involved in elastin degradation in vivo
 
,
 
 macrophage-
elastin cocultures have been used as an alternate means to
characterize the elastolytic potential of specific MMPs (8–15).
To date, human macrophages have not been reported to
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Abbreviations used in this paper:
 
 ECM, extracellular matrix; MDM, monocyte-
derived macrophage; MMP, matrix metalloproteinase; MT1, membrane
type 1; TIMP-2, tissue inhibitor of metalloproteinases-2; tPA, tissue-type
plasminogen activator; uPA, urokinase-type plasminogen activator.T
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use MMPs to degrade elastin efficiently in vitro
 
,
 
 thus sup-
porting the contention that these cells may use this class of
proteinases in an indirect fashion to support elastolytic
events in vivo (9, 12–15). However, as macrophages cul-
tured in vitro seldom recapitulate the full spectrum of elas-
tolytic MMPs expressed in vivo, the significance of these
findings has remained unclear (1–6, 12–15). Herein, we
have isolated and characterized human monocyte-derived
macrophages (MDMs), which express a repertoire of elas-
tin-degrading enzymes similar, if not identical, to those
found in vivo. Significantly, these cells display an MMP-
dependent elastolytic phenotype hundreds of times greater
than that previously reported. Moreover, despite the fact
that these macrophages efficiently express gelatinase B as
well as metalloelastase, neither MMP played a major role in
the elastin-degradative phenotype. Instead, maximal MMP-
dependent elastolytic activity was conferred by the plas-
min-mediated processing of the metalloproteinase zymogen,
promatrilysin, to its catalytically active form. As matrilysin-
dependent elastin degradation by MDMs is further comple-
mented by an independent system of cosecreted elastolytic
cysteine proteinases (15, 16), we posit that these two pro-
teolytic systems together define the tissue-destructive po-
tential of human macrophages in vivo.
 
Materials and Methods
 
Macrophage Preparation.
 
Human peripheral blood monocytes
were either adherence purified as previously described (15, 16) or
isolated by negative selection using the MACS Monocyte Isolation
Kit (Miltenyi Biotec; reference 17) and cultured for 9 d in RPMI
1640 (Invitrogen) supplemented with 40% autologous serum. Al-
ternatively, monocytes were differentiated atop an ECM-derived
substratum deposited by MDCK cells (18) for 9 d and then dis-
lodged from the matrix by washing the cells in Hank’s buffered salt
solution (without Ca
 
 
 
2 
 
and Mg
 
 
 
2
 
) supplemented with 10 mM
EDTA. The cells were then transferred to nontissue culture–
treated plates for 24 h before assay. Control cells were treated in an
identical fashion except for the fact that the 9-d differentiation pro-
cess proceeded atop standard bacteriologic culture dishes.
Macrophages were isolated from gelatinase B
 
 
 
/
 
  
 
mice (129/
SvEv genetic background; reference 19), metalloelastase
 
 
 
/
 
  
 
mice
(mixed 129/SvEv and C57BL6 background; reference 3), or the
respective wild-type littermates after the intraperitoneal injection of
thioglycollate medium (Becton Dickinson). After 4 d, peritoneal
macrophages were harvested, adherence purified, and allowed to
further mature for 72 h in RPMI 1640 supplemented with a 1:1
mixture of 40% heat-inactivated (56
 
 
 
C for 30 min) fetal bovine se-
rum (HyClone) and 40% heat-inactivated human serum.
 
RNA Purification, cDNA Synthesis, In Vitro Transcription, and
Array Hybridization.
 
RNA was isolated with TRIzol reagent
(GIBCO BRL) from purified nonadherent human monocytes as
well as from cultured cells. Poly A
 
  
 
RNA was purified with Oli-
gotex (QIAGEN). cDNA was synthesized with a SuperScriptII
cDNA synthesis kit (Invitrogen) and used as a template for in
vitro transcription using the Megascript system (Ambion). cRNA
was labeled and hybridized as previously described (16) using a
custom-designed chip to screen for elastases. Biotinylated hybrid-
ized cRNA was developed by staining with streptavidin-PE and
the arrays were scanned (16).
 
Determination of Plasminogen Activator and Plasmin Activity As-
say.
 
After 9 d in culture, MDMs were cultured under serum-free
conditions for 24 h, cell-free supernatants were recovered, and
urokinase-type plasminogen activator (uPA) and tissue-type plas-
minogen activator (tPA) levels were determined by ELISA (Amer-
ican Diagnostica, Inc.). Plasmin activity was determined in MDM
cultures supplemented with 50 
 
 
 
g/ml human glu-type plasmino-
gen (Calbiochem-Novabiochem) under serum-free conditions. Af-
ter a 24-h incubation, aliquots of cell-free supernatant were assayed
for plasmin activity using the SpectrozymePL chromogenic sub-
strate (American Diagnostica, Inc.; reference 20). One unit of ac-
tivity was defined as the amount of plasmin needed to hydrolyze
1.0 
 
 
 
mol of substrate per minute at 25
 
 
 
C, pH 7.8.
 
Elastin Preparation and Elastolytic Assay.
 
Elastin (type E60;
Elastin Products Co.) was reductively labeled (800–900 cpm/
 
 
 
g
elastin) as previously described (15, 16). Human or mouse macro-
phages were cocultured with [
 
3
 
H]elastin (8 mg total), which was
placed in a transwell insert (3-
 
 
 
m pore size; Corning, Inc.) and
suspended above the cell cultures in serum-free RPMI 1640. Al-
ternatively, macrophage-mediated elastin degradation in the pres-
ence of cell–substrate contact was assessed by adding 8 mg
[
 
3
 
H]elastin directly atop the cell monolayer. Where indicated,
macrophage/[
 
3
 
H]elastin cocultures were incubated alone, with 50
 
 
 
g/ml glu-type human plasminogen, 100 
 
 
 
g/ml mouse-neutral-
izing antibody against human uPA (American Diagnostica, Inc.),
mouse anti–gelatinase B IgG (ab-2; reference 21), 50 
 
 
 
g/ml nor-
mal mouse IgG (both from Oncogene Research Products and
Calbiochem-Novabiochem), recombinant human pro–MMP-7
(Chemicon International, Inc.), recombinant human pro–gelati-
nase B and A (R&D Systems), 5 
 
 
 
M of the synthetic MMP inhibi-
tor, BB94 (0.1% DMSO final; provided by British Biotechnol-
ogy; reference 22), 5 
 
 
 
g/ml endotoxin-free recombinant human
tissue inhibitor of metalloproteinases-2 (TIMP-2; Fuji Chemical
Industries, LTD.; reference 22), 100 
 
 
 
M the pan-specific cysteine
proteinase inhibitors, E-64 (0.05% ethanol final; Sigma-Aldrich;
reference 16), 100 
 
 
 
g/ml aprotinin (Roche; reference 22), 5 
 
 
 
M
the aspartate protease inhibitor, pepstatin (0.05% ethanol final;
Roche; reference 23), or solvents (0.1% DMSO and 0.05% etha-
nol) alone. At 24-h intervals, solubilized [
 
3
 
H]elastin was quanti-
tated in cell-free supernatants by 
 
 
 
-scintillation counting. Ap-
proximately 1.5% of the total radioactivity associated with the
elastin particles could be released by plasmin. [
 
3
 
H]elastin “pre-
stripped” with plasmin was equally sensitive to MDM-dependent
proteolysis or elastolysis by purified MMPs (unpublished data).
Results are expressed as mean 
 
  
 
SEM.
 
Degradation of Aortic Elastin Ex Vivo.
 
Segments of rat aorta
were devitalized after three rounds of freezing (in liquid nitrogen)
and thawing. MDMs were cocultured with aortic tissue that was
placed into a transwell insert and suspended above the macro-
phages in the absence or presence of 50 
 
 
 
g/ml plasminogen. Af-
ter a 10-d culture period, aortic segments were removed, fixed in
4% paraformaldehyde, embedded in paraffin, and sectioned.
 
Western Blot Analysis and Zymography.
 
After 9 d in culture,
macrophages were switched to serum-free medium and cultured
either alone (for 48 h) or with elastin in the upper well of a
transwell dish for 5 d. Where indicated, 50 
 
 
 
g/ml plasminogen,
0.5 
 
 
 
g/ml recombinant human pro–gelatinase A, and protease
inhibitors were added as described above to MDM-elastin co-
cultures. Aliquots of conditioned media or Triton X-114 ex-
tracts (for membrane type 1 [MT1]-MMP; reference 20) were
incubated alone or with either 3 mM 4-aminopherylmercuric
acetate (Sigma-Aldrich) or 1 
 
 
 
g/ml trypsin (Sigma-Aldrich) for
1 h at 25
 
 
 
C to activate MMP proenzymes (20). To recover pro-T
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teases bound to the elastin surface, elastin particles were washed
in the presence of a protease inhibitor cocktail (Set III; Calbio-
chem). The elastin was then placed in a boiling solution of elu-
tion buffer (62.5 mM Tris-Cl, 2% SDS, 10% vol/vol glycerol, 2
mM dithiothreitol, 0.01% Bromophenol blue, pH 6.8) for 10
min and the elastin-free supernatant was recovered. Equal
amounts (10 
 
 
 
g) of protein from the conditioned media or elas-
tin surface were loaded under reducing conditions onto a 12.5%
SDS-polyacrylamide gel and transferred to PVDF membrane
(Amersham Biosciences; reference 22). The membranes were
then incubated with rabbit anti–macrophage metalloelastase
polyclonal antisera (4), rat anti–MMP-7 monoclonal antibody
 
 
 
hMat338 (24), or rabbit anti–gelatinase-B polyclonal antisera
(provided by H. Welgus, Pfizer Inc., Ann Arbor, MI). The
bound primary antibodies were then detected with horseradish
peroxidase–conjugated species-specific secondary antibodies
(Pierce Chemical Co.) using the SuperSignal West Pico system
(Pierce Chemical Co.; references 16 and 22).
For zymography, samples of conditioned media or gelatinase A
standards were resolved under nonreducing conditions on 12.5%
polyacrylamide gels impregnated with 2 mg/ml gelatin as previ-
ously described (23).
 
Elastolytic Activity of Recombinant Enzymes.
 
Enzyme concen-
trations were determined by active site titration with the stoichio-
metric inhibitor TIMP-2 (25). To assess elastolytic potential, 1.0
pmol active site–titrated gelatinase B, matrilysin, or metal-
loelastase were incubated alone or in combination with [
 
3
 
H]elas-
tin in serum-free media at 37
 
 
 
C for 5 d. Solubilized [
 
3
 
H]elastin
was quantitated as described above.
 
Results
 
MMP-dependent Elastolysis.
 
To obtain a comprehen-
sive profile of the elastolytic enzymes expressed by human
monocytes during ex vivo differentiation, cRNA from
freshly isolated or cultured cells was probed for transcripts
belonging to the MMP, cysteine proteinase, or serine pro-
teinase gene families. Although the repertoire of MMPs ex-
pressed by freshly isolated monocytes is limited to gelati-
Figure 1. Expression of elastolytic
MMPs and elastolysis by differentiat-
ing MDMs. (A) Expression of elas-
tolytic proteinases was assessed in
monocytes (Mo) and MDMs after 1,
2, 3, 5, 7, and 9 d in culture by oligo-
nucleotide array analysis. Elastase 1, 2,
IIB, and IIIA are pancreatic elastase I,
neutrophil elastase, pancreatic elastase
II, and pancreatic endopeptidase E,
respectively. Results are shown as a
color-coded increase in mRNA
content relative to that expressed by
freshly isolated nonadherent mono-
cytes from a single representative
experiment of three performed. (B)
Secretory phenotype of MDMs.
Mature MDMs were incubated for
48 h in serum-free media. Aliquots
of conditioned media or membrane
extracts (for MT1-MMP) were re-
solved by SDS-PAGE and probed
with specific antibodies. The ability
of MT1-MMP to process gelatinase
A was assessed by gelatin zymography
(lower right-hand section of panel).
MDMs were incubated for 48 h in
serum-free media alone (lane 3) or
cocultured with 0.5  g/ml progelati-
nase A in the absence (lane 4) or
presence (lane 5) of BB-94. Stan-
dards for the proforms and processed
forms of gelatinase A as well as the
gelatinase A proenzyme are shown
in lanes 1 and 2, respectively. The
proforms (open arrowheads) and
processed (arrows) forms of enzymes
are indicated. Results are shown from
a single representative experiment of
three performed. (C) MDMs were
cocultured with [3H]elastin sus-
pended in the upper well of a transwell insert to prevent direct cell–elastin contact in the absence (  and  ) or presence (  and  ) of 50  g/ml exogenous
plasminogen. Elastolysis was monitored over the course of a 5-d culture period. Elastolysis was inhibited by BB-94 under both plasminogen-free ( ) or
plasminogen-supplemented conditions ( ). Results are expressed as the mean   SEM (n   5). (D) Human MDMs were cocultured for 10 d with aortic
tissue in the absence or presence of 50  g/ml plasminogen and BB-94. Appearance of the aortic elastin is shown on cross sections by hematoxylin and
eosin staining. Arrows indicate zones of elastin fragmentation and asterisks show intact elastic lamina ( 100). The appearance of the full thickness sections
is shown in the insets ( 20).T
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nase A (MMP-2) and MT1-MMP, the differentiation
process triggers the up-regulation of gelatinase B (MMP-9),
metalloelastase (MMP-12), and matrilysin (MMP-7; Fig. 1
A). Western blot analysis confirmed the ability of the fully
differentiated (i.e., 9-d-old) macrophages to synthesize the
proforms of gelatinase B, human metalloelastase, and
matrilysin as well as the processed form of MT1-MMP
(Fig. 1 B), but not the proforms or active forms of gelati-
nase A (Fig. 1 B). As previously reported (15, 16), 9-d-old
MDMs also express the elastolytic cysteine proteinases, ca-
thepsin L, K, and S (Fig. 1 A). Under these conditions, the
expression of elastin-degrading serine proteinases is not de-
tected (Fig. 1 A).
To determine the ability of MDMs to use secreted
MMPs as elastolytic effectors, [
 
3
 
H]-labeled elastin fragments
were placed in a transwell insert and suspended above the
cell cultures in the absence or presence of the peptidomi-
metic MMP inhibitor, BB-94. Despite the fact that MDMs
only secrete proforms of the MMPs, 
 
 
 
80 
 
 
 
g of elastin is
degraded over a 5-d culture period via a BB-94–sensitive
process (Fig. 1 C). Although elastolysis could potentially be
augmented by the MT1-MMP–dependent activation of
exogenous gelatinase A (26), MDMs are unable to process
recombinant progelatinase A to its active form under these
culture conditions despite the expression of processed
MT1-MMP (Fig. 1 B).
To characterize the status of the plasminogen activator–
plasminogen axis as a potential MMP activating system in
macrophages, uPA and tPA expression were monitored as
well as the ability of the cells to process plasminogen to
plasmin. After 9 d in culture, MDMs synthesize 453 
 
  
 
18
pg uPA/10
 
6 
 
cells for 24 h while tPA could not be detected.
In the presence of 50 
 
 
 
g/ml exogenous plasminogen, 680 
 
 
 
16 mU of plasmin activity is generated via a process that
can be inhibited completely by either anti-uPA blocking
monoclonal antibody or the serine proteinase inhibitor,
aprotinin (unpublished data). Consistent with the ability of
plasmin to efficiently process pro-MMPs to active forms (8,
27), MDM-mediated elastin degradation increased from
106 
 
  
 
18 
 
 
 
g/10
 
6 
 
cells for 5 d under plasminogen-free con-
ditions to 1,100 
 
  
 
150 
 
 
 
g (
 
n 
 
  
 
5; mean 
 
  
 
1 SEM) in the
presence 50 
 
 
 
g/ml plasminogen (Fig. 1 C). BB-94 inhib-
ited plasminogen-dependent elastolysis by 93 
 
  
 
4% (
 
n 
 
  
 
3)
without affecting plasmin activity (unpublished data).
Although purified elastin provides a convenient substrate
for quantifying elastolytic activity, the elastic lamellae found
in situ are more complex structures comprised primarily of
elastin as well as microfibrillar and other proteins (8). To
determine the tissue-destructive potential of MDMs con-
fronted with a physiologically relevant substrate, cells were
cultured with devitalized aortic vessel explants. Although
thinning and fragmentation of the elastic lamina of the aortic
explants is discerned in MDM cocultures in the absence of
plasminogen (Fig. 1 D, top left), almost complete dissolution
of the elastin sheets is observed when MDMs are supple-
mented with plasminogen (Fig. 1 D, top right). As observed
with purified elastin, BB-94 completely protects the elastic
lamina from MDM-mediated damage without affecting plas-
min generation (Fig. 1 D). Thus, macrophages can degrade
elastin via MMP-dependent processes in either the absence
or presence of plasminogen.
 
Plasminogen-independent Elastolysis.
 
MDMs degrade
elastin under plasminogen-free conditions by either mobi-
Figure 2. Plasminogen-independent proteolysis by human and mouse
macrophages. (A) Human MDMs were cocultured with [3H]elastin
(suspended in the upper well of a transwell insert) under plasminogen-
free conditions in the absence or presence of inhibitors directed against
metallo (5  M BB-94 or 5  g/ml TIMP-2), serine (100  g/ml aprotinin),
cysteine (100  M E-64), or aspartate (5  M pepstatin) proteinases as well
as solvent controls (0.1% DMSO and 0.05% ethanol) as indicated. Results
are shown as  g elastin degraded/106 cells for 5 d (mean   SEM; n   6).
(B and C) Left: Plasminogen-independent processing and elastolytic
activity of MMP zymogens. Human macrophages and elastin were co-
cultured in the absence or presence of 5  M BB-94 for 5 d. The processing
of progelatinase B (B) and prometalloelastase (C) in the absence of
plasminogen (plg) was assessed by Western blot analysis in samples recovered
from conditioned media or the elastin surface. The proforms (open arrow-
heads) and mature (arrows) forms of enzymes are indicated. Results are
shown from a single representative experiment of three performed.
Right: Mouse macrophages obtained from gelatinase B /  (Gel.B / ) or
gelatinase B /  (Gel.B / ) mice (B) and metalloelastase /  (MME / ) or
MME /  mice (C) were incubated with [3H]elastin in the absence
or presence of BB-94 for 5 d. Results are shown as  g elastin degraded/
106 cells for 5 d (mean   SEM; n   3).T
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lizing MMPs alone or using MMPs in collaboration with
other proteolytic systems that serve to process latent forms
of the metalloproteinases to their catalytically active forms
(28). To determine whether MMP-dependent elastolysis
involves other proteinase classes, MDMs were cultured
with elastin particles in the presence of inhibitors directed
against the serine (aprotinin, soybean trypsin inhibitor),
cysteine (E-64), or aspartyl (pepstatin) proteinase families.
Whereas either BB-94 or the native MMP inhibitor,
TIMP-2, block elastin degradation by  80%, none of the
other inhibitors affect elastolytic activity (Fig. 2 A). Al-
though these results support a direct role for one or more
MMPs in elastin degradation, the means by which the
MMP zymogens are activated and the identity of the elas-
tolysin(s) remain undefined. Because MMP zymogens may
bind to the elastin surface and undergo conformational
changes that allow for the expression of proteolytic activity
(4, 29, 30), MDMs were cocultured with elastin and the
distribution as well as processing of the MMPs were moni-
tored in both the cell-free supernatant as well as the elastin
surface. As observed in MDMs cultured alone (Fig. 1 B),
progelatinase B (Fig. 2 B) and promatrilysin (unpublished
data) are the predominant species detected in the media of
MDM-elastin cocultures in either the absence or presence
of BB-94. Although only trace amounts of promatrilysin
are recovered from the elastin surface (unpublished data),
progelatinase B is readily found in association with elastin
particles (Fig. 2 B).
Recent studies suggest that the progelatinase B zymogen
can express proteolytic activity after binding to the appropri-
ate substrate (30), but gelatinase B–specific inhibitors are not
currently available for testing. Hence, the degradative poten-
tial of macrophages isolated from gelatinase B /  or gelatinase
B-null mice was compared directly. As shown in Fig. 2 B,
cultured mouse macrophages degrade elastin to a degree
comparable to human MDMs under plasminogen-free con-
ditions via a BB-94–sensitive process (Fig. 2 B). However, al-
though mouse macrophages constitutively release gelatinase
B (5), gelatinase-null macrophages continue to exert an elas-
tolytic effect indistinguishable from control cells (Fig. 2 B).
Although active forms of neither gelatinase B nor matril-
ysin were generated in MDM-elastin cocultures, both pro-
forms and processed forms of metalloelastase are found in
the conditioned media as well as elutes recovered from the
elastin particles (Fig. 2 C). Consistent with a role for elastin
in catalyzing the autoactivation process, BB-94 blocked the
formation of the  18-kD active form on the particle sur-
face (Fig. 2 C). As these findings support a potential role for
metalloelastase in plasminogen-independent proteolysis by
human cells, the elastolytic potential of metalloelastase / 
and metalloelastase-null mouse macrophages was assessed.
Significantly, the metalloelastase-null cells display little, if
any, elastolytic activity despite normal gelatinase B expres-
sion (Fig. 2 C and unpublished data). Given the ability of
human metalloelastase to bind to elastin and undergo pro-
cessing to active forms, coupled with the loss of elastolytic
activity displayed by metalloelastase-null mouse macro-
phages, these data imply that metalloelastase, and not gelati-
nase B, plays a required role in macrophage-mediated elas-
tin degradation under plasminogen-free conditions.
Figure 3. Plasminogen-dependent elastolysis and pro-
cessing of MMP zymogens by human MDMs. (A) Human
MDMs were cocultured with [3H]elastin in the upper well
of a transwell insert with 50  g/ml plasminogen (plg) in
the absence or presence of the indicated inhibitors. Results are
shown as  g elastin degraded/106 cells for 5 d (mean   SEM;
n   3). Western Blots: MDMs and elastin were cocultured
without contact in the presence of 50  g/ml plasminogen
and/or 100  g/ml aprotinin for 5 d. The processing of
progelatinase B (B), prometalloelastase (C), and promatrilysin
(D) in the presence of plasminogen was assessed by Western
blot analysis in samples recovered from conditioned media or
the elastin surface. The proforms (open arrowheads) and
mature (arrows) forms of enzymes are indicated. The
processing of the proforms by 4-aminopherylmercuric acetate
or trypsin are shown at the far right of each panel with the
proforms (open arrowheads) and mature (arrows) forms
depicted. Results are shown from a single representative
experiment of three performed.T
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Plasminogen-dependent Elastolysis. By contrast with the
plasminogen-independent system, MDM-dependent elas-
tolysis in the presence of plasminogen is not only sensitive
to BB-94 and TIMP-2, but to the plasmin inhibitor, apro-
tinin, as well. (Consistent with plasmin-dependent release
of  1–2% of the radioactivity associated with the elastin
particles [refer to Materials and Methods], aprotinin inhib-
ited elastolysis slightly more effectively than BB-94 or
TIMP-2 alone; Fig. 3 A). Further, plasmin-dependent elas-
tolysis is accompanied by the aprotinin-sensitive processing
of the progelatinase B and promatrilysin zymogens to ma-
ture forms that comigrate with the active species in both
the cell-free conditioned media and at the elastin surface
(Fig. 3, B and D). In the case of metalloelastase, plasmin
catalyzed the processing of the zymogen to species no
longer detectable in the conditioned media or on the elas-
tin surface (Fig. 3 C). Although prometalloelastase and its
processed products are recovered when plasmin activity is
blocked with aprotinin, the  18-kD active form of metal-
loelastase is not stabilized in the presence of BB-94 (Fig. 3
C). Apparently, the steady state concentration of active
metalloelastase is below detectable limits as a consequence
of plasmin-dependent turnover.
Matrilysin Confers Macrophages with Elastolytic Activity.
To determine the relative roles of gelatinase B, matrilysin,
and metalloelastase in plasminogen-dependent elastolysis by
Figure 4. Matrilysin “deficiency” abrogates
plasminogen-dependent elastolysis by human
MDMs and mouse peritoneal macrophages.
(A) Mouse peritoneal macrophages or human
monocytes differentiated for 9 d atop the
surface of either bacteriologic plastic dishes
(Plastic) or a cell-derived ECM (Matrix;
phase micrographs are shown on the right of
A) were cultured with elastin suspended in
transwell inserts as described in Fig. 1 in the
absence or presence of 50  g/ml plasminogen
(plg). Where indicated, macrophages were
incubated with or without 5  M BB-94. In
the presence of plasminogen and BB-94,
the release of radiolabel from elastin is due
primarily to plasmin activity and can be re-
duced to background levels with aprotinin
(unpublished data). Results are shown as  g
elastin degraded/106 cells for 5 d (mean  
SEM;  n     3). (B) Secretion of elastolytic
MMPs by human MDMs and murine macro-
phages as a function of in vitro culture con-
ditions. Human MDMs differentiated atop
surfaces of bacteriologic plastic (Plastic) or
the cell-derived matrix (Matrix) were cultured
under  serum-free conditions for 48 h.
Conditioned media was collected and analyzed
by immunoblot for gelatinase B, human
metalloelastase (HME), and matrilysin. Mouse
macrophages were cultured in bacteriologic
plastic  dishes for 48 h under serum-free
conditions and conditioned media was ana-
lyzed for MMPs by immunoblot as described
in Fig. 1. (C) Human MDMs were cocultured
with [3H]elastin and incubated alone (lane 1),
with 50  g/ml plasminogen (plg; lane 2), or
plasminogen in the presence of aprotinin
(lane 3), BB-94 (lane 4), anti–gelatinase B
antibody (lane 5), or normal mouse IgG
(both 50  g/ml; lane 6). MMP-9 processing
was assessed by gelatin zymography (top) and
the effects on degradative activity were
quantified (bottom). Results are expressed
as   g elastin degraded/106  cells for 5 d
(mean   SEM; n   3). (D) Human MDMs
differentiated atop a cell-derived matrix
(Matrix) or mouse peritoneal macrophages
cultured under standard conditions (Plastic) were incubated with [3H]elastin and 50  g/ml plasminogen in the absence or presence of 5  M BB-94.
Where indicated, 20 nM recombinant promatrilysin was added to the culture system in the absence or presence of BB-94. 20 nM recombinant
promatrilysin and 25  g/ml plasmin were also incubated with elastin under cell-free conditions (Cell-Free). Inset shows the relative levels of matrilysin
detected in media conditioned by human MDMs (M  CM) and the amount of recombinant matrilysin added (rMMP-7). Results are expressed as  g
elastin degraded/106 cells for 5 d (mean   SEM; n   3). (E) Equimolar quantities (1.0 pmol) of active site–titrated gelatinase B, human metalloelastase, or
matrilysin alone, or all three enzymes together were incubated with [3H]elastin in serum-free media at 37 C. Results are expressed as  g elastin degraded
for 5 d (mean   SEM; n   3).T
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human MDMs, the ability of mouse macrophages to de-
grade elastin in the presence of plasminogen was examined
as a prelude to testing the elastolytic potential of the respec-
tive MMP-null littermates. Unexpectedly, however, the
ability of wild-type mouse macrophages to degrade elastin
in the presence of plasminogen was not augmented to the
levels observed with human MDMs despite efficient plas-
min generation by the mouse cells (Fig. 4 A).
As an alternative approach to assign roles to the individ-
ual MMPs in macrophage-mediated proteolysis, efforts
were initiated to generate an elastolytic-incompetent hu-
man macrophage population that would afford the oppor-
tunity to characterize critical differences that underlie the
acquisition of the destructive phenotype. As monocyte dif-
ferentiation can be regulated by the physical characteristics
of the underlying substratum (31), human monocytes were
cultured atop various matrices and elastolytic activity was
assessed. Interestingly, when human monocytes are differ-
entiated atop a cell-derived ECM, plasminogen-dependent
proteolysis by MDMs is suppressed from  1,200 to  200
 g elastin degraded (Fig. 4 A). Given that the ability of the
matrix-differentiated macrophages to generate plasmin ac-
tivity remains unchanged (680 vs. 760 mU of plasmin
activity generated by plastic- vs. matrix-differentiated MDMs,
respectively), MMP expression was monitored by Western
blot analysis. Although human metalloelastase synthesis is
unaffected, gelatinase B expression is partially depressed
whereas matrilysin is no longer produced under these con-
ditions (Fig. 4 B).
The decrease in gelatinase B and/or matrilysin expres-
sion by matrix-cultured MDMs correlates with their ob-
served loss in elastin-degrading activity. If gelatinase B plays
a required role in the elastolytic process after its plasmin-
dependent processing to active species, then blocking anti-
bodies that interfere with the activation process should
suppress proteolysis. However, when plasmin-dependent
gelatinase B processing is blocked completely with an anti–
gelatinase B monoclonal antibody, elastolytic activity is not
affected (Fig. 4 C). Furthermore, macrophage-mediated
proteolysis is only enhanced modestly by supplementing
MDM cultures with 0.5  g/ml exogenous progelatinase B
(a 28% increase relative to control cultures; n   2).
To next determine if the decrease in matrilysin expres-
sion by matrix-cultured MDMs could be linked to the loss
in elastolytic activity, matrilysin-deficient macrophages
were supplemented with recombinant promatrilysin at lev-
els similar to those expressed by MDMs cultured under
standard conditions. In the presence of 20 nM promatril-
ysin, the ability of matrix-cultured MDMs to degrade elas-
tin is recovered completely (Fig. 4 D). Furthermore, the
failure of wild-type mouse macrophages to up-regulate
elastolytic activity in the presence of plasminogen (Fig. 4
A) also correlates with the reported inability of these cells
to express matrilysin in vitro (Fig. 4 B; reference 32). As in
the case of matrix-cultured MDMs, the elastolytic activity
of mouse macrophages is similarly augmented by exoge-
nous matrilysin to levels comparable to those expressed by
human macrophages (Fig. 4 D).
The fact that matrilysin rescues the depressed proteolytic
activity of matrix-cultured MDMs or wild-type mouse
macrophages is consistent with the ability of the proteinase
to either alter cell function or serve as a direct acting elas-
tolysin (32–35). To determine the relative activities of
gelatinase B, metalloelastase, and matrilysin as elastin-degrad-
ing proteases, equimolar quantities of the active site–titrated
enzymes were incubated with radiolabeled elastin. Al-
though gelatinase B and metalloelastase were able to pro-
teolyze elastin, matrilysin is sixfold more efficient as an
elastolysin (Fig. 4 E). Synergistic interactions between the
three MMPs are not detected (Fig. 4 E). Further, a mixture
of 20 nM recombinant promatrilysin and 25  g/ml plas-
min fully recapitulates the elastolytic activity of intact
MDMs (Fig. 4 D). The addition of progelatinase B or pro-
metalloelastase to the cell-free system does not further aug-
ment activity (unpublished data). Thus, plasminogen-depen-
dent proteolysis by human MDMs can be largely, if not
entirely, ascribed to the plasmin–matrilysin axis.
Cysteine Proteinases Complement MMP-dependent Elastolysis
by Human MDMs. Coincident with an expression of
MMPs, human macrophages can constitutively secrete a se-
Figure 5. Cysteine proteinases complement MMP-dependent elastolysis
by human MDMs. (A) MDMs were incubated with [3H]elastin to allow
cell–substrate contact and elastolysis was monitored in the absence ( ) or
presence ( ) of 50  g/ml exogenous plasminogen (plg) over the course
of a 5-d culture period. Results are expressed as the mean   SEM (n  
4). (B) MDMs were cocultured in contact with elastin in the absence
(gray bar) or presence (solid bar) of plasminogen for 5 d alone or with
either 100  M E-64 alone or E-64 in combination with either 5  m
BB-94, 5  g/ml TIMP-2, or 100  g/ml aprotinin. Results are shown
as  g elastin degraded/106 cells for 5 d (mean   SEM; n   3).T
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ries of elastolytic cysteine proteinases including cathepsins
S, L, and K (15, 16). However, in contrast to MMPs, cys-
teine proteinase activity is strictly confined to the macro-
phage–elastin interface within acidified zones maintained
by a vacuolar-type H -ATPase (15, 16). To determine
whether MMPs can complement the elastolytic activity of
cysteine proteinases, elastin was added to MDM cultures to
initiate direct contact between the cell and substrate. In the
absence of plasminogen, MDM–elastin contact triggers a
large increase in elastin degradation (i.e., 1,200   5  g/106
cells for 5 d; Fig. 5, A and B) relative to that observed in
the absence of cell–substrate contact ( 100  g; Fig. 1 C).
Under these conditions, the bulk of the elastin degradation
was sensitive to the specific cysteine proteinase inhibitor,
E-64, with only small increases in inhibition observed
when MMP activity was blocked with BB-94 (Fig. 5 B).
However, in the presence of plasminogen, elastin degrada-
tion is increased dramatically to over 2,000  g/106 cells for
5 d. Although E-64 is only able to decrease elastolysis by
 50% to 1,092   28  g/106 cells for 5 d in the presence of
plasminogen, the residual activity is mediated by MMPs
and proves sensitive to inhibition by BB-94, TIMP-2, or
aprotinin (Fig. 5 B). Thus, in the presence of cell–elastin
contact, MMPs and cysteine proteinases together arm
MDMs with their maximal proteolytic activity.
Discussion
Studies in gene-deleted mice have identified roles for
metalloelastase and gelatinase B in cigarette smoke–induced
emphysema and macrophage-dependent aneurysm forma-
tion, respectively (3, 7, 8). As each of these MMPs express
elastolytic activity in cell-free systems, it has been assumed
that active metalloelastase and gelatinase B play similar roles
in vivo by mediating directly the dissolution of elastin-rich
tissues (3, 7, 8). However, these conclusions have been
questioned as each of these MMPs has been shown to regu-
late proinflammatory effects in vivo via largely unexpected
mechanisms (9–11). For example, in animal models of em-
physema, metalloelastase-deleted macrophages display de-
fects in tumor necrosis factor expression that alter the subse-
quent recruitment of tissue-destructive polymorphonuclear
leukocytes (6). Furthermore, in proinflammatory states
characterized by the expression of a complex mixture of
MMPs (e.g., IL-13–induced models of chronic obstructive
pulmonary disease), metalloelastase-null mice mount a
blunted response associated with a failure to up-regulate a
series of downstream proteinases (37). Similarly, gelatinase
B–deficient mice display altered inflammatory responses af-
ter tissue damage (38, 39). Given the multiplicity of changes
observed in vivo after the deletion of either metalloelastase
or gelatinase B (36–39), attempts to assign specific ECM
substrates to either MMP in pathophysiologic settings have
been met with limited success. Indeed, where MMPs have
been implicated directly in tissue-destructive states in vivo,
recent studies identified probable target substrates as plasma-
derived proteinase inhibitors or latent proinflammatory me-
diators, rather than ECM molecules per se (10, 11).
To circumvent the complexities inherent in attempts to
identify specific substrates for a given MMP, we turned to
an ex vivo model wherein MDMs are cultured with elastin
(either in the form of isolated fragments or as native elastic
lamina) to identify the proteinases in the macrophage rep-
ertoire that are capable of directly mediating elastolytic ef-
fects. To more accurately mimic the in vivo state, MDMs
were further cultured under conditions where they
expressed gelatinase B, metalloelastase, MT1-MMP, and
matrilysin, a complement of MMPs similar, if not identical,
to that found in macrophages surrounding sites of elastin
damage in vivo (1, 2, 9). Under optimal conditions,
MDMs were able to use MMPs to degrade elastin in quan-
tities hundred of times greater than previously assigned to
this family of proteinases (12–15), thus prompting efforts to
identify the key mediators involved.
In vivo studies have identified a role for the plasminogen
activator–plasminogen axis in elastolytic states, but the pro-
teolytic activity of this system is dictated by the local con-
centration of plasminogen activator and plasminogen as
well as plasminogen activator and plasmin inhibitors (5, 6,
27). Using plasminogen-free conditions to mimic condi-
tions under which the plasminogen activator–plasminogen
axis would be inactive or neutralized, MDMs were found
to express limited, but significant, elastolytic activity. Based
on recent findings that substrate binding can unmask latent
MMP activity (29, 30), we considered the possibility that
elastin degradation might be mediated by elastin-bound ge-
latinase B. However, gelatinase B–null macrophages de-
graded elastin comparably to wild-type cells and recombi-
nant progelatinase B did not initiate an elastolytic effect
when cultured with elastin fragments under cell-free condi-
tions. Instead, elastin degradation was found to correlate
with the binding of metalloelastase to elastin and its subse-
quent processing to an active elastolysin. The proteinase(s)
responsible for generating the multiple metalloelastase prod-
ucts found in association with the elastin surface has not yet
been identified, but apparently does not belong to the me-
talloproteinase family as the spectrum of metalloelastase frag-
ments detected in the cocultures was unaffected by the ad-
dition of MMP inhibitors. Nonetheless, the final processing
of the metalloelastase zymogen to a species with a Mr simi-
lar, if not identical, to active metalloelastase was blocked
completely by BB-94. Further, by using macrophages iso-
lated from gene-deleted mice, we demonstrated that metal-
loelastase-null macrophages were unable to degrade elastin
under plasminogen-free conditions. Although metalloelastase-
dependent elastolysis has not previously been proposed to
occur in the absence of plasmin (8, 39), these data are con-
sistent with a model wherein the MMP binds to the elastin
surface where it is cleaved by uncharacterized proteinases to
generate fragments that undergo autocatalytic processing to
generate the active enzyme. We considered the possibility
that plasminogen-independent elastolysis might be aug-
mented by the MT1-MMP–mediated activation of gelati-
nase A (26), but MDMs were unable to process the exoge-
nously supplied proenzyme. Although the mechanism
underlying the inability of MT1-MMP to activate gelati-T
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nase A was not examined in our study, similar defects have
been ascribed to a failure to oligomerize the membrane-
anchored MMP at the cell surface (40).
By contrast with the limited elastolytic effect observed
under plasminogen-free conditions, the ability of MDMs to
degrade elastin was increased over 10-fold via the uPA-
dependent activation of plasminogen to plasmin. As expected,
plasminogen-dependent elastolysis was accompanied by the
processing of the gelatinase B, metalloelastase, and matril-
ysin zymogens (6, 27). In an effort to identify the relative
roles of each of these MMPs in the elastin-degradative phe-
notype, initial efforts focused on using macrophages recov-
ered from the respective gene-deleted mice. However,
mouse macrophages were unable to up-regulate their elas-
tolytic potential in the presence of plasminogen, despite ef-
ficient plasmin generation. Although these findings appear
to contradict earlier studies, it should be noted that murine
macrophages have been previously reported to express a
much more limited degradative phenotype than that re-
ported here (i.e., in the presence of plasminogen, murine
macrophages only degrade 5  g/106 cells for 24 h), pre-
sumably due to an in vitro culture protocol that blunts the
elastolytic potential of mouse macrophages.
As an alternate to using MMP-null murine macrophages,
human monocytes were cultured atop an ECM-coated sur-
face to generate elastolytically incompetent cells. Previous
studies have demonstrated that the culture substratum used
to support monocyte differentiation can regulate cell phe-
notype (31). Although matrix-cultured MDMs no longer
degrade elastin effectively relative to the standard culture
system used here, the uPA–plasmin axis was unaffected and
metalloelastase was synthesized at normal levels. However,
gelatinase B and matrilysin levels were depressed, though to
different degrees. Given our inability to implicate gelatinase
B in plasminogen-dependent elastin degradation, attention
focused on the fact that the depressed elastolytic activity of
matrix-cultured MDMs correlated with the loss of matril-
ysin expression. Likewise, the failure of mouse macro-
phages to augment elastolytic activity in the presence of
plasminogen was also linked to the apparent inability of
these cells to express matrilysin in vitro (32). Signifi-
cantly, when either matrilysin-“deficient” human MDMs
or mouse macrophages were supplemented with physiologi-
cal concentrations of promatrilysin, elastolytic activity was
reconstituted to the levels observed for fully active human
MDMs. As matrilysin has been shown to play key roles in
host defense and inflammation by virtue of its ability to
process antibacterial factors and shed membrane-anchored
growth factors, cell adhesion molecules, cytokines, or pro-
teoglycans (32–35), these findings seemed most consistent
with the possibility that matrilysin affected elastolytic activ-
ity by altering macrophage function. However, of the three
MMPs tested, matrilysin proved to be the most effective
elastolysin, and after plasmin activation, physiologically rel-
evant concentrations of matrilysin degraded elastin compa-
rably to intact MDMs. Consistent with our analyses of
macrophage-mediated elastin degradation, the elastolytic
potential of matrilysin under cell-free conditions was not
enhanced significantly by either gelatinase B or metal-
loelastase. Thus, we conclude that the uPA–plasminogen–
matrilysin axis confers macrophages with their most potent
MMP-dependent elastolytic activity.
In addition to the ability of human macrophages to mo-
bilize MMPs, recent studies have highlighted the impor-
tance of an independently functioning family of elastolytic
cysteine proteinases (15, 16). During the differentiation
process, MDMs not only up-regulate the expression of a
triad of elastolytic cysteine proteinases including cathepsins
L, S, and K, but also acquire the ability to secrete active
forms of these proteinases into the extracellular milieu (15,
16). In the pericellular environment, cathepsin S, L, and K
activities are restricted to the cell–substrate interface where
an acidified microenvironment is generated to support the
catalytic activity of the acidophilic cysteine proteinases (15,
16). Additional studies with gene-deleted mouse macro-
phages have identified cathepsin L and S as the major cys-
teine proteinases responsible for this effect (unpublished
data). Thus, in the presence of macrophage–elastin contact,
the bulk of the elastolytic phenotype observed under plas-
minogen-free conditions can be linked to these two cys-
teine proteinases. By contrast, in the presence of plasmino-
gen, elastin degradation was increased dramatically with
both cysteine proteinases and MMPs working in concert to
arm macrophages with the ability to degrade milligram
quantities of elastin. Although we attempted to determine
the degree to which matrilysin participates in the elastolytic
process in the presence of macrophage–elastin contact, the
ECM-differentiated MDMs no longer bound the elastin
particle tightly (unpublished data), a prerequisite condition
for cysteine proteinase–dependent proteolysis (15, 16).
Nonetheless, the relatively modest elastolytic activity as-
signed to gelatinase B or metalloelastase in either our intact
cell system or under cell-free conditions, makes it unlikely
that either of these MMPs play a major role in the presence
of macrophage–elastin contact. This issue notwithstanding,
depending on the absence or presence of macrophage–elas-
tin contact and the local concentration of plasmin in the
pericellular milieu, our findings demonstrate that macro-
phages can mediate elastolysis by mobilizing either cysteine
proteinases or MMPs, alone or in combination.
In this study, efforts have focused on identifying elas-
tolytic mediators mobilized by human or murine macro-
phages, but these results should not be misconstrued to
suggest that proteinases such as gelatinase B or metal-
loelastase play less important roles in tissue-destructive
states in vivo. By hydrolyzing antiproteinases, chemokines,
growth factors, and cytokines, many MMP family members
appear to exert their most important effects by targeting
non-ECM substrates (9–11). Nonetheless, although in vivo
studies can provide critical insights into the role played by
individual proteinases in complex outcomes, only indirect
correlations can be established between an expressed or de-
leted proteinase and an observed effect (9). Using ex vivo
models that faithfully recapitulate specific components of
the inflammatory process, tissue-destructive mediators can
be identified unequivocally and targeted for further testing.T
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Indeed, although caution must be exercised in extrapolat-
ing results from the mouse macrophage to its human coun-
terpart (e.g., reference 41), or to assuming the direct actions
of a given proteinase in an in vivo setting (9), cysteine pro-
teinases and MMPs have recently been linked to tissue-
destructive effects in mouse models of atherosclerosis, chronic
obstructive pulmonary disease, or pulmonary fibrosis (42–
44). The demonstration that human macrophages are
armed not only with a subset of tissue-destructive MMPs,
but also a series of elastolytic cysteine proteinases as well,
underscores the complex interplay that exists between dis-
tinct proteolytic systems and suggests that therapeutics
aimed at select members of both gene families might be
necessary to ameliorate elastolytic effects in vivo.
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